lost in pennyland
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We know the RM is coming. That's an open secret. If we get some momo going we can run this into the double digits easily with such a low float. When a move gets announced it will launch from there.
Take the points. The bears are going to win it outright. I'm still unsure about 48 as the total. My first thought was go over 48.
If we hit .05 today we'll hit double digits Monday. The float is so low here that any momo will send the price soaring. With the reverse merger coming shortly this is a green light, similar to what XKEM did leading up to the announcement of their approval.
We know Abe Grossman bought this to reverse merge it. We know the last company he reverse merged went to $6.50 a share after the rm was announced. Ten cents will be cheap once the announcement is made.
We're in a great position here.
So then what is the share count here?
I will too. It really looked like it was ready to run today, but slow steady growth is just fine with me.
The best thing about it is that we know he's familiar with how a public company is run. He's not just coming into the public markets cold from the laboratory. He's been able to observe up close and personal for a few years now what it takes to move the markets.
It also gives CSBR potential inroads to partnerships with other emerging biotechs. They clearly came into this venture with a plan already in place.
You're right, he joined CSBR in 2001. It appears that he came on board to help find a new direction for the company.
I think they found a beauty. :)
Can we construe any meaning from the Sec filing yesterday, or not?
I think a number of traders are afraid to take a chance right now because the price has moved so far already. They're willing to wait for it to come down and if it doesn't, so be it. The traders on this site all talk about gaps when reading the charts.
I'm concentrating on the gap between the few hundred thousand dollars that Champions sports bar brought in per year vs. the billions that a successful biotech can bring in per year.
What a crock! Keith obviously doesn't give a rat's ass about his shareholders, or he wouldn't have diluted their shares into the ground. Get a clue.
How about going public through a reverse merger with a company already making, or about to make money.
Does that ever happen?
Either that or they want to begin the dilution cycle all over again. Take your pick.
You wanna play a little russian roulette?
ADNL soon ADNN with a 10,000:1 reverse split.
Just look at level 2. Count the asks posted. There are only 7 asks between the current price and $2.00.
Just seven trades to $2.00 now.
Any news release about developing a test that detects the major forms of cancer earlier than current methods and we're off to the $5 to $40 range. This is based on the current OS and the going rate for developmental biotechs with a blockbuster product or products in the pipeline.
When you connect all of the dots here, you get a very pretty picture.
1. As early as the mid-90s Dr. Sidransky's group discusses the possibility of detecting a universal screening test for cancer.
2. In '03 they're researching a method to detect both head and neck and lung cancer simultaneously.
3. In a recent study they reveal a test that detected lung cancer in a man a year before it was dianosed by current methods.
4. The professional connections include current FDA director Dr. Andrew Von Eschenbach, whom he wrote papers and conducted research with.
5. He recently served on the board of directors at Imclone with Carl Icahn, who is a major investor in biotech (particularly imclone).
6. He served on a scientific board with current presidential candidate Tommy Thompson.
I think that the R&D phase of Champions Biotechnology has been carried out over the last 15 years. They're now ready to commercialize a product (or products) and go public.
This study from 2003 shows Dr. Sidransky's research team creating a test for lung and head and neck cancer. They point out that lung cancer is the most deadly form of cancer, and that the assay they created would be cheap. This would make a clinical study fairly cost effective.
http://jnci.oxfordjournals.org/cgi/content/full/95/22/1711?ck=nck
Hello .80!
Great post. And what insurance company wouldn't pay for the test if it's accuracy was proven and it could save billions in health care costs?
Millions of baby boomers being screened yearly for early detection of lung cancer. The money made from this would be used to develop detection methods for the other major cancers.
He's understating it by a factor of about 100. Diagnostic screenning tests for the major cancers could be worth billions in market cap.
That's the potential. As I posted earlier the field that Dr. Sidranksy is at the forefront of is considered by leading oncologists to be the next major breakthrough in the fight against cancer.
I don't think so, but I sure like to see the bids stacking in the teens and 20's in anticipation of the next leg up.
An announcement of a partnership between Champions biotech and Johns Hopkins to develop diagnostic screening tests for all of the major forms of cancer would bring in big investors and take us well into the dollars.
Better get those bids filled soon boys and girls.
I agree, Martel has something to add with his 20 years of experience running a public company. He will be handy with the financial details, which will leave the doctors to concentrate on bringing in the most promising aspects of the science.
Obviously the doctors have been meticulous in shaping their stellar careers. It would lead us to believe that they will practice the same care in putting their names behind a public company.
In that regard it's likely that they have been planning this move for some time. They probably didn't come into this venture empty-handed.
They are the three owners that have decided to begin a biotech. The remaining 7 million shares constitute the float.
Nice to finally confirm the intentions of the docs. They are moving fairly quickly. I expect a news release with more details about champions biotech soon.
Thanks, that's a fascinating piece.
Hey guys here's another bottom play for biotechnology. CSBR just announced a name change to reflect a change in company direction. They're a fully reporting company with only 27 million shares outstanding.
The new name is Champions Biotechnology. Earlier in the month two prominent doctors from Johns Hopkins bought 10,000,000 shares of the company. Today's announcement confirms the reason for their buy.
Dr. David Sidransky and Dr. Manuel Hidalgo are at the forefront in the research on diagnostic testing, which is considered by oncologists to be the next major breakthrough in the fight against cancer.
Dr. Sidransky is a consultant for numerous biotechs and has formed a number of private biotech companies already. He has many patents also.
Looks like we have ourselves a biotech company. Congrats to everyone who held. Let's see that dollar now (and then some)!
How'd you get it that low? lol
I just spoke with the owner of a public shell company about bringing a private company through his shell. He told me that it takes 6 weeks minimum to complete an audit for a company with any operations at all, and anyone who says anything different hasn't been through the process.
He said that private companies keep books, but they usually find out that those books weren't thorough enough. It's a long and expensive process.
We know that Aero has loads of operations, so the timetable laid out by FCCN/AERO is in line with what the shell owner described.
You could argue that they could have done this ahead of time, but if the process is as demanding as the shell owner elaborated, no one in their right mind would begin the process until a definitive agreement had been reached.
There has also been a large buyer in this that usually comes in about noon...
THIS is the way a public company is supposed to work.
Aero rewards us by running a great company and we reward them by buying their share price higher.
Still 7 trades to 1.00. WHO WANTS TO BE A HERO?
CSBR will become legendary in penny world.
We'll open well above that.
Another advance Dr. Lichter discussed in the NPR interview was new treatments to reduce the toxicity of current cancer drugs.
As we know from the recent post of Dr. Sidransky's research, this is another area that his group has been targeting.
I bought stock in Aero Exhaust at 3 cents. Pretty soon people will be saying, "yeah right, and I bought Apple at 10 cents."
No really, I did.
Aero Exhaust wants to be listed on the AMEX or NASDAQ. What is the price target for each?
Good morning fellow Aero Exhaust shareholders!
Companies that habitually reverse split their stock will always be valued based on their rate of dilution. Jeff dilutes his company so fast that the market cap will probably reach 10 million before I finish typing this post.
The value of your shares is diluted around the clock so that Mr. Flannery can pay for all of the acqusitions like the one he just made.
I agree that eventually one of these ventures is bound to pay off for lucky investors. In fact, look what AXGJ did recently before it's inevitable collapse.
Someday he might turn the dilution machine off and actually pay for his business ventures with profits from his business operations...
I'm such a dreamer.
It's not going to take that long. We ARE Aero now. Bring on the massive PR campaign!
Don't WE already have a deal with Ford?
And WE'RE co-sponsoring car 37 with Toyota?
WE'RE the official muffler of NASCAR?
What was that last PR? WE just became the official muffler of another racing circuit?
GENTLEMEN, START YOUR ENGINES!!!!!!!!!!!!!!
Cancer is the lead story on the CBS evening news as I speak.
Cancer rates are down for the 2nd year in a row. "Progress is occuring in prevention, early detection and treatment."
1500 still die from cancer every day in the US. But the death rates are decreasing in every type of cancer, except lung cancer for women, which is leveling off.